Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.

Cancer letters - 1 Aug 2024

Lu Youwei, Sun Yu, Zhang Jie, Kong Miao, Zhao Zhiming, Sun Boshu, Wang Yuan, Jiang Ying, Chen Shaomu, Wang Chao, Tong Yin, Wen Liangzhu, Huang Moli, Wu Fengying, Zhang Liang

Abstract excerpt

B7-H4 is an immune checkpoint crucial for inhibiting CD8+ T-cell activity. A clinical trial is underway to investigate B7-H4 as a potential immunotherapeutic agent. However, the regulatory mechanism of B7-H4 degradation via the ubiquitin-proteasome pathway (UPP) remains poorly understood. In this study, we discovered that proteasome inhibitors effectively increased B7-H4 expression, while EGFR-activating mutants...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mice, Nude

Share to Proteasome Endopeptidase Complex

Share to Ubiquitin Thiolesterase

Source

Identifiers

PMID: 38849009
DOI: 10.1016/j.canlet.2024.217020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.PMID 38849009Read ↗

Downregulation of B7-H4 contributes to the synergistic effect of USP2a-targeted/anti-PD-1 combination therapy in EGFR mutant lung cancer.Semantic proximity Read ↗

Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatmentSemantic proximity Read ↗

Ubiquitin-specific peptidase 10, a deubiquitinating enzyme: Assessing its role in tumor prognosis and immune responseSemantic proximity Read ↗

Targeting deubiquitinase USP28 for cancer therapySemantic proximity Read ↗

Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathwaysSemantic proximity Read ↗

F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategiesSemantic proximity Read ↗

Targeting ubiquitin specific protease 7 in cancer: A deubiquitinase with great prospectsSemantic proximity Read ↗

Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer ImmunotherapySemantic proximity Read ↗

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer developmentSemantic proximity Read ↗

The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in CancerSemantic proximity Read ↗

A pan-cancer analysis of USP5: its diagnostic, prognostic and immunological roles in human cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.